Extrawell Pharmaceutical Holdings (HKSE:00858) Cash-to-Debt : 0.82 (As of Sep. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Extrawell Pharmaceutical Holdings's cash to debt ratio for the quarter that ended in Sep. 2023 was 0.82.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Extrawell Pharmaceutical Holdings couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Extrawell Pharmaceutical Holdings's Cash-to-Debt or its related term are showing as below:

HKSE:00858' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.82 Med: 3.33 Max: 8.67
Current: 0.82

During the past 13 years, Extrawell Pharmaceutical Holdings's highest Cash to Debt Ratio was 8.67. The lowest was 0.82. And the median was 3.33.

HKSE:00858's Cash-to-Debt is ranked worse than
52.11% of 1019 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs HKSE:00858: 0.82

Extrawell Pharmaceutical Holdings Cash-to-Debt Historical Data

The historical data trend for Extrawell Pharmaceutical Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Extrawell Pharmaceutical Holdings Cash-to-Debt Chart

Extrawell Pharmaceutical Holdings Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

3.04

1.99

1.74

1.33

1.01

Extrawell Pharmaceutical Holdings Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial															1.56	1.33	8.67	1.01	0.82

Competitive Comparison of Extrawell Pharmaceutical Holdings's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Extrawell Pharmaceutical Holdings's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Extrawell Pharmaceutical Holdings's Cash-to-Debt falls into.

Extrawell Pharmaceutical Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Extrawell Pharmaceutical Holdings's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	104.155	/	(1.316	+	101.908)
	=	1.01

Extrawell Pharmaceutical Holdings's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	91.499	/	(1.34	+	110.018)
	=	0.82

Extrawell Pharmaceutical Holdings (HKSE:00858) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Extrawell Pharmaceutical Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Extrawell Pharmaceutical Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Extrawell Pharmaceutical Holdings (HKSE:00858) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG

Website

http://www.extrawell.com.hk

Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.

Executives

Mao Yumin	2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited	2201 Interest of corporation controlled by you
Ease Gold Investments Limited	2201 Interest of corporation controlled by you
Jnj Investments Ltd	2201 Interest of corporation controlled by you
United Gene Group Ltd	2201 Interest of corporation controlled by you
United Gene Holdings Limited	2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited	2101 Beneficial owner
Xie Yi	2201 Interest of corporation controlled by you
Huang Zhenping	2101 Beneficial owner
United Gene Industry Group Limited	2101 Beneficial owner
Chen Xuhua	2202 Interest of your spouse
Cheng Yong	2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings (HKSE:00858) Headlines

No Headlines